Boehringer Ingelheim
-
Boehringer Ingelheim single combination of telmisartan and amlodipine provides 24-hour blood pressure reduction and control
Boehringer Ingelheim has released a new anti-hypertensive drug (TWYNSTA) containing a unique combination of telmisartan and amlodipine. Very often, hypertension sufferers take up to four drugs to reach an acceptable blood pressure (BP) more effectively. The single-pill combination drug is taken once daily and provides additional therapeutic and cardiovascular (CV) benefits.
Boehringer Ingelheim | 02 February 2012
-
Boehringer Ingelheim licenses ProBioGen's GlymaxX technology
Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive licensing agreement regarding ProBioGen’s GlymaxX technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (…
Boehringer Ingelheim | 11 August 2011
-
Boehringer Ingelheim to start new growth phase in 2011
2010 was for Boehringer Ingelheim the year in which it reached 125 years of age. The jubilee year also brought new alliances for the future. With Eli Lilly and Company, Boehringer Ingelheim will develop and market active substances for diabetes that …
Boehringer Ingelheim | 09 May 2011
-
Boehringer Ingelheim’s lead hepatitis C compound moves into phase 3
Boehringer Ingelheim announced the study outline for the pivotal phase 3 clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and experienced patients with chronic genotype-1 …
Boehringer Ingelheim | 04 April 2011
